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Résumé en
anglais
2,5-Dimethoxy-4-propylphenethylamine (2C-P) is a hallucinogenic designer drug of
the phenethylamine class, the so-called 2Cs, named according to the ethyl spacer
between the nitrogen and the aromatic ring. The aims of the present work were to
identify the phases I and II metabolites of 2C-P. In addition, the detectability of 2C-
P and its metabolites in urine as proof of an intake in clinical or forensic cases was
tested. According to the identified metabolites, the following pathways were
proposed: N-acetylation; deamination followed by reduction to the corresponding
alcohol and oxidation to carbonic acid; mono- and bis-hydroxylation at different
positions; mono- and bis-O-demethylation, followed by glucuronidation, sulfation,
or both; and combination of these steps. Proof of an intake of a common user's
dose of 2C-P was possible by both standard urine screening approaches, the GC-
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